Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Burning Rock Partner for Oncology MDx

NEW YORK (GenomeWeb) – Illumina and molecular diagnostics firm Burning Rock announced today that they will codevelop oncology products based on Illumina's sequencing instruments for the Chinese market.

As part of the agreement, Illumina will provide NGS instrument components and reagents and Guangzhou, China-based Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software.

"We have been working to promote the clinical application of genomic technology in China," Burning Rock Founder and CEO Yusheng Han said in a statement. "Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."

The collaboration will "increase access to oncology diagnosis solutions in China," Rick Klausner, Illumina's senior VP and chief medical officer, said in a statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.